Concepedia

Author

Yasuko Asahina

Pharmaceuticals and Medical Devices Agency

Also Known As

Y Asahina, Y. ASAHINA, Y. Asahina, Yasuko ASAHINA, Yasuko Asahina

22

Publications

253

Citations

8

H-Index

9

Concepts

All Affiliations

Pharmaceuticals and Medical Devices AgencyChiba University
YA

About

Yasuko Asahina is an author at Pharmaceuticals and Medical Devices Agency specializing in medicine, biochemistry, and natural sciences.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

14

2

Natural Sciences

1

1

14

3

Biochemistry

1

1

14

4

Microbiology

1

1

14

5

Molecular Biology

1

1

14

Yasuko Asahina

×

8

Publications

217

Citations

8

H-Index

YearCitations

Significant Differences in Drug Lag in Clinical Development Among Various Strategies Used for Regulatory Submissions in Japan

Takeshi Ueno, Yasuko Asahina, Akio Tanaka,

Clinical Pharmacology & Therapeutics

2013

71

Magnetic support for neutrino-driven explosion of 3D non-rotating core-collapse supernova models

Jin Matsumoto, Yasuko Asahina, Tomoya Takiwaki,

Monthly Notices of the Royal Astronomical Society

2022

36

Regulatory Science as a Bridge Between Science and Society

Toshiyoshi Tominaga, Yasuko Asahina, Yoshiaki Uyama,

Clinical Pharmacology & Therapeutics

2011

30

Similarities and Differences between US and Japan as to Pharmacogenomic Biomarker Information in Drug Labels

Yasuto Otsubo, Yasuko Asahina, Atsushi Noguchi,

Drug Metabolism and Pharmacokinetics

2011

29

Regulatory activities to address the needs of older patients

Francesca Cerreta, R Temple, Yasuko Asahina,

The journal of nutrition health & aging

2014

14

Structures of the SEp22 dodecamer, a Dps-like protein from<i>Salmonella enterica</i>subsp.<i>enterica</i>serovar Enteritidis

Takanori Miyamoto, Yasuko Asahina, Shohei Miyazaki,

Acta Crystallographica Section F Structural Biology and Crystallization Communications

2010

14

Representation of older patients in clinical trials for drug approval in Japan

Yasuko Asahina, Hajime Sugano, Eiko Sugiyama,

The journal of nutrition health & aging

2014

12

Systemic administration of the antisense oligonucleotide <scp>NS</scp> ‐089/ <scp>NCNP</scp> ‐02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I/ <scp>II</scp> clinical trial

Takami Ishizuka, Hirofumi Komaki, Yasuko Asahina,

Neuropsychopharmacology Reports

2023

11

Page 1